PDGFRA and gastrointestinal stromal tumor: Taken together, although the length of the follow-up may have an impact on these results, avapritinib treatment in metastatic PDGFRA D842V-mutant GIST patients appears to improve the outcomes to a greater extent than first-line treatment.